細胞表面マーカー検出の世界市場：市場規模・シェア分析 (製品別・用途別)、産業収益の推計と需要の予測 (～2030年)

世界の細胞表面マーカー検出の市場規模は、2023年に55億550万米ドルで、2030年には94億2,740万米ドルに達し、予測期間中に8.1%の成長率で推進します。この産業の原動力となっているのは、精密医療への要求の高まり、体外診断の受容度の上昇、スループットと自動化率を高める技術の進歩です。

フローサイトメトリー装置が市場をリード

フローサイトメトリー装置は、2023年には35%と最大のシェアを占めました。これは主に、この方法が同じサンプルで多数のパラメーターを測定でき、数秒で数百万の細胞からデータを収集できるためです。

創薬・研究が最も急成長する用途

創薬・研究分野は2030年までに8.4%と業界で最も急成長します。その主な理由は、慢性疾患の増加と、それに伴う医療費の急増です。

ある報告書によると、2000年、米国では慢性疾患を1つ以上持つ人は1億2,000万人を超えていました。この数は2030年まで毎年1%以上増加します。

したがって、2000年から2030年の間に、北米で慢性疾患を抱える人の数は約40%、約5,000万人急増することになります。

北米は地域リーダー

北米は2023年には55%のシェアを占め、同市場の地域リーダーです。これは、技術進歩、高齢者人口の増加、慢性疾患の罹患率の増加によるものです。

アジア太平洋が最速の成長を遂げる

アジア太平洋はこの10年末までに最も速い成長を遂げると思われます。これは主に高齢者の増加と、最近の創薬や研究、特に遺伝子治療の進歩によるものです。また、CVD、糖尿病、がんの患者数が増加していることも、この業界の原動力となっています。

インドでは、がんに罹患する人の数が2021年の約2,700万人から2025年には約3,000万人に増加すると予想されています。

当レポートでは、世界の細胞表面マーカー検出の市場について分析し、市場の基本構造・最新情勢や主な促進・抑制要因、世界全体および地域別・主要国の市場規模の動向見通し (金額ベース、2017～2030年)、製品別・用途別の詳細動向、現在の市場競争の状況、主要企業のプロファイルなどを調査しております。

目次

第1章 調査範囲

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場指標

第5章 業界の展望

• 市場力学
  • 動向
  • 促進要因
  • 抑制要因/課題
  • 促進要因/抑制要因の影響分析
• 新型コロナウイルス感染症 (COVID-19) の影響
• ポーターのファイブフォース分析

第6章 世界市場

• 概要
• 市場収益：製品別 (2017～2030年)
• 市場収益：用途別 (2017～2030年)
• 市場収益：地域別 (2017～2030年)

第7章 北米市場

• 概要
• 市場収益：製品別 (2017～2030年)
• 市場収益：用途別 (2017～2030年)
• 市場収益：国別 (2017～2030年)

第8章 欧州市場

第9章 アジア太平洋市場

第10章 ラテンアメリカ市場

第11章 中東・アフリカ (MEA) 市場

第12章 米国市場

• 概要
• 市場収益：製品別 (2017～2030年)
• 市場収益：用途別 (2017～2030年)

第13章 カナダ市場

第14章 ドイツ市場

第15章 フランス市場

第16章 英国市場

第17章 イタリア市場

第18章 スペイン市場

第19章 日本市場

第20章 中国市場

第21章 インド市場

第22章 オーストラリア市場

第23章 韓国市場

第24章 ブラジル市場

第25章 メキシコ市場

第26章 サウジアラビア市場

第27章 南アフリカ市場

第28章 アラブ首長国連邦 (UAE) 市場

第29章 競合情勢

• 市場参入企業とその提供製品/サービスの一覧
• 主要企業の競合ベンチマーク
• 主要企業の製品ベンチマーク
• 最近の戦略展開状況

第30章 企業プロファイル

• Abbott Laboratories
• Becton, Dickinson and Company
• Nihon Kohden Corporation
• Thermo Fisher Scientific Inc.
• Sysmex Corporation
• Janssen Diagnostics Inc.
• Grifols SA
• Siemens Healthcare
• BioRad Laboratories Inc.
• F. Hoffmann-La Roche Ltd.

第31章 付録

The size of the cell surface marker detection market was USD 5,505.5 million in 2023, and it will touch USD 9,427.4 million by 2030, propelling at a rate of 8.1% during the projection period. The industry is powered by the increase in the requirement for precision medicine, the increase in the acceptance of in vitro diagnostics, and tech advancements that enhance throughput and the automation rate.

Drivers of the Industry

Cell surface markers help in recognizing high-risk patients precisely, enhancing the accuracy of the diagnosis, progressing follow-up policies for people, estimating susceptibility to targeted therapy or immunotherapy, and predicting prognostic outcomes.

Precision medicine is used in the treatment of many subspecialties, mostly in cancer and inherited diseases, for both diagnosis and treatment, using next-gen sequencing.

Precision medicine reduces the cost of care and advances the overall health of people through the use of pharmacogenomics, which uses patient data to create effective and safe plans for the medication of patients.

Precision medicine is a cutting-edge method of altering the approaches to disease prevention and treatment.

It will allow doctors and researchers to predict more precisely the most appropriate treatment with information on the molecular and genetic makeup of the patient, environment, and lifestyle.

Flow Cytometry Instruments Led the Market

The flow cytometry instruments had the largest share, of 35%, in 2023. This is principally because this method can measure numerous parameters in the same sample and collect data from millions of cells within seconds.

Moreover, with this method, any non-uniformity in a uniform cell populace is detected, and it also eliminates all the dead cells or debris when the final data is provided.

Drug Discovery and Research is the Fastest Growing Application

The drug discovery and research category will grow the fastest in the industry, with a rate of 8.4%, by 2030. This is mostly because of the increasing occurrence of chronic ailments and the resulting surge in healthcare spending.

As per a report, in 2000, in the U.S., people with over one chronic condition were over 120 million. This number will increase by over 1% every year till 2030.

Hence, between 2000 and 2030, the number of people in North America with chronic conditions will surge by about 40% or around 50 million individuals.

North America is the Regional Leader

North America was the regional leader of the market, with a 55% share, in 2023, because of the growing count of tech progressions, surging elderly population, and growing incidence of chronic diseases.

In the U.S., there is an increase in the count of citizens aged 65 and more. This share of the elderly people in the total populace will rise to about 24% by 2060 from 15% in 2016.

The aging population is more susceptible to chronic ailments, for example, cardiac conditions, gastrointestinal issues, and cancer. Moreover, the U.S. is the 5th globally for age-standardized rates for all cancers.

APAC To Experience Fastest Growth

APAC will have the fastest growth by the end of this decade. This is mostly due to the increasing number of elderly people and recent advances in drug discovery and research procedures, particularly in gene therapy. The rising populace of patients with CVDs, diabetes, and cancer is also powering the industry.

In India, the number of people suffering from cancer will increase to about 30 million in 2025 from approximately 27 million in 2021.

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by product
  • 1.4.2. Market size breakdown, by application
  • 1.4.3. Market size breakdown, by region
  • 1.4.4. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

• 5.1. Market Dynamics
  • 5.1.1. Trends
  • 5.1.2. Drivers
  • 5.1.3. Restraints/challenges
  • 5.1.4. Impact analysis of drivers/restraints
• 5.2. Impact of COVID-19
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Bargaining power of buyers
  • 5.3.2. Bargaining power of suppliers
  • 5.3.3. Threat of new entrants
  • 5.3.4. Intensity of rivalry
  • 5.3.5. Threat of substitutes

Chapter 6. Global Market

• 6.1. Overview
• 6.2. Market Revenue, by Product (2017-2030)
• 6.3. Market Revenue, by Application (2017-2030)
• 6.4. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

• 7.1. Overview
• 7.2. Market Revenue, by Product (2017-2030)
• 7.3. Market Revenue, by Application (2017-2030)
• 7.4. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

• 8.1. Overview
• 8.2. Market Revenue, by Product (2017-2030)
• 8.3. Market Revenue, by Application (2017-2030)
• 8.4. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

• 9.1. Overview
• 9.2. Market Revenue, by Product (2017-2030)
• 9.3. Market Revenue, by Application (2017-2030)
• 9.4. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

• 10.1. Overview
• 10.2. Market Revenue, by Product (2017-2030)
• 10.3. Market Revenue, by Application (2017-2030)
• 10.4. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

• 11.1. Overview
• 11.2. Market Revenue, by Product (2017-2030)
• 11.3. Market Revenue, by Application (2017-2030)
• 11.4. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

• 12.1. Overview
• 12.2. Market Revenue, by Product (2017-2030)
• 12.3. Market Revenue, by Application (2017-2030)

Chapter 13. Canada Market

• 13.1. Overview
• 13.2. Market Revenue, by Product (2017-2030)
• 13.3. Market Revenue, by Application (2017-2030)

Chapter 14. Germany Market

• 14.1. Overview
• 14.2. Market Revenue, by Product (2017-2030)
• 14.3. Market Revenue, by Application (2017-2030)

Chapter 15. France Market

• 15.1. Overview
• 15.2. Market Revenue, by Product (2017-2030)
• 15.3. Market Revenue, by Application (2017-2030)

Chapter 16. U.K. Market

• 16.1. Overview
• 16.2. Market Revenue, by Product (2017-2030)
• 16.3. Market Revenue, by Application (2017-2030)

Chapter 17. Italy Market

• 17.1. Overview
• 17.2. Market Revenue, by Product (2017-2030)
• 17.3. Market Revenue, by Application (2017-2030)

Chapter 18. Spain Market

• 18.1. Overview
• 18.2. Market Revenue, by Product (2017-2030)
• 18.3. Market Revenue, by Application (2017-2030)

Chapter 19. Japan Market

• 19.1. Overview
• 19.2. Market Revenue, by Product (2017-2030)
• 19.3. Market Revenue, by Application (2017-2030)

Chapter 20. China Market

• 20.1. Overview
• 20.2. Market Revenue, by Product (2017-2030)
• 20.3. Market Revenue, by Application (2017-2030)

Chapter 21. India Market

• 21.1. Overview
• 21.2. Market Revenue, by Product (2017-2030)
• 21.3. Market Revenue, by Application (2017-2030)

Chapter 22. Australia Market

• 22.1. Overview
• 22.2. Market Revenue, by Product (2017-2030)
• 22.3. Market Revenue, by Application (2017-2030)

Chapter 23. South Korea Market

• 23.1. Overview
• 23.2. Market Revenue, by Product (2017-2030)
• 23.3. Market Revenue, by Application (2017-2030)

Chapter 24. Brazil Market

• 24.1. Overview
• 24.2. Market Revenue, by Product (2017-2030)
• 24.3. Market Revenue, by Application (2017-2030)

Chapter 25. Mexico Market

• 25.1. Overview
• 25.2. Market Revenue, by Product (2017-2030)
• 25.3. Market Revenue, by Application (2017-2030)

Chapter 26. Saudi Arabia Market

• 26.1. Overview
• 26.2. Market Revenue, by Product (2017-2030)
• 26.3. Market Revenue, by Application (2017-2030)

Chapter 27. South Africa Market

• 27.1. Overview
• 27.2. Market Revenue, by Product (2017-2030)
• 27.3. Market Revenue, by Application (2017-2030)

Chapter 28. U.A.E. Market

• 28.1. Overview
• 28.2. Market Revenue, by Product (2017-2030)
• 28.3. Market Revenue, by Application (2017-2030)

Chapter 29. Competitive Landscape

• 29.1. List of Market Players and their Offerings
• 29.2. Competitive Benchmarking of Key Players
• 29.3. Product Benchmarking of Key Players
• 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

• 30.1. Abbott Laboratories
  • 30.1.1. Business overview
  • 30.1.2. Product and service offerings
  • 30.1.3. Key financial summary
• 30.2. Becton, Dickinson and Company
  • 30.2.1. Business overview
  • 30.2.2. Product and service offerings
  • 30.2.3. Key financial summary
• 30.3. Nihon Kohden Corporation
  • 30.3.1. Business overview
  • 30.3.2. Product and service offerings
  • 30.3.3. Key financial summary
• 30.4. Thermo Fisher Scientific Inc.
  • 30.4.1. Business overview
  • 30.4.2. Product and service offerings
  • 30.4.3. Key financial summary
• 30.5. Sysmex Corporation
  • 30.5.1. Business overview
  • 30.5.2. Product and service offerings
  • 30.5.3. Key financial summary
• 30.6. Janssen Diagnostics Inc.
  • 30.6.1. Business overview
  • 30.6.2. Product and service offerings
  • 30.6.3. Key financial summary
• 30.7. Grifols SA
  • 30.7.1. Business overview
  • 30.7.2. Product and service offerings
  • 30.7.3. Key financial summary
• 30.8. Siemens Healthcare
  • 30.8.1. Business overview
  • 30.8.2. Product and service offerings
  • 30.8.3. Key financial summary
• 30.9. BioRad Laboratories Inc.
  • 30.9.1. Business overview
  • 30.9.2. Product and service offerings
  • 30.9.3. Key financial summary
• 30.10. F. Hoffmann-La Roche Ltd.
  • 30.10.1. Business overview
  • 30.10.2. Product and service offerings
  • 30.10.3. Key financial summary

Chapter 31. Appendix

• 31.1. Abbreviations
• 31.2. Sources and References
• 31.3. Related Reports